NASDAQ:CRNX
Crinetics Pharmaceuticals Inc Stock News
$47.47
-1.16 (-2.39%)
At Close: May 24, 2024
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nov
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
07:10am, Wednesday, 03'rd Feb 2021
Phase 1 study is designed to provide clinical proof-of-concept by taking advantage of established methods in endocrinology Phase 1 study is designed to provide clinical proof-of-concept by taking adva
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference
07:05am, Wednesday, 06'th Jan 2021
- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 -
Crinetics Pharmaceuticals to Participate in December Investor Conferences
07:30am, Monday, 23'rd Nov 2020
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December.
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
07:30am, Monday, 16'th Nov 2020
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nove
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
07:30am, Friday, 13'th Nov 2020
Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
08:31am, Friday, 06'th Nov 2020
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trial s of oral paltusotine for the treatment of acromegaly
Crinetics Pharmaceuticals- Superior Molecules In Endocrinology
01:35pm, Tuesday, 01'st Sep 2020
Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Increased to Hold at BidaskClub
01:22am, Tuesday, 11'th Aug 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday, BidAskClub reports. Several other analyst
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
11:30am, Friday, 07'th Aug 2020
Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study a
Crinetics Pharmaceuticals (NASDAQ:CRNX) Downgraded by BidaskClub to Sell
05:48am, Sunday, 19'th Jul 2020
BidaskClub downgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a hold rating to a sell rating in a research note issued to investors on Wednesday, BidAskClub reports. CRNX has been the s
Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly
08:05pm, Wednesday, 08'th Jul 2020
SAN DIEGO, July 08, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics fo
Should You Avoid Crinetics Pharmaceuticals, Inc. (CRNX)?
09:29pm, Sunday, 05'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
H.C. Wainwright Thinks Minerva Neurosciences' Stock is Going to Recover - Markets
10:07am, Thursday, 02'nd Jul 2020
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Minerva Neurosciences (NERV – Research
Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved (NASDAQ:CHMA)
04:31pm, Tuesday, 30'th Jun 2020
On Friday, June 26, 2020, the FDA approved CHMA's Mycapssa. Shares fell on the news to reflect a market cap of ~$250MM and an enterprise valuation of less than
